Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Leukocyte-mimicking nanovesicles for effective doxorubicin delivery to treat breast cancer and melanoma.

Molinaro R, Martinez JO, Zinger A, De Vita A, Storci G, Arrighetti N, De Rosa E, Hartman KA, Basu N, Taghipour N, Corbo C, Tasciotti E.

Biomater Sci. 2019 Nov 12. doi: 10.1039/c9bm01766f. [Epub ahead of print]

PMID:
31714542
2.

Macrophage-derived nanovesicles exert intrinsic anti-inflammatory properties and prolong survival in sepsis through a direct interaction with macrophages.

Molinaro R, Pastò A, Corbo C, Taraballi F, Giordano F, Martinez JO, Zhao P, Wang X, Zinger A, Boada C, Hartman KA, Tasciotti E.

Nanoscale. 2019 Jul 28;11(28):13576-13586. doi: 10.1039/c9nr04253a. Epub 2019 Jul 10.

PMID:
31290914
3.

Design and Development of Biomimetic Nanovesicles Using a Microfluidic Approach.

Molinaro R, Evangelopoulos M, Hoffman JR, Corbo C, Taraballi F, Martinez JO, Hartman KA, Cosco D, Costa G, Romeo I, Sherman M, Paolino D, Alcaro S, Tasciotti E.

Adv Mater. 2018 Apr;30(15):e1702749. doi: 10.1002/adma.201702749. Epub 2018 Mar 7.

PMID:
29512198
4.

Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.

Martinez JO, Molinaro R, Hartman KA, Boada C, Sukhovershin R, De Rosa E, Kirui D, Zhang S, Evangelopoulos M, Carter AM, Bibb JA, Cooke JP, Tasciotti E.

Theranostics. 2018 Jan 5;8(4):1131-1145. doi: 10.7150/thno.22078. eCollection 2018.

5.

Engineered biomimetic nanovesicles show intrinsic anti-inflammatory properties for the treatment of inflammatory bowel diseases.

Corbo C, Cromer WE, Molinaro R, Toledano Furman NE, Hartman KA, De Rosa E, Boada C, Wang X, Zawieja DC, Agostini M, Salvatore F, Abraham BP, Tasciotti E.

Nanoscale. 2017 Oct 5;9(38):14581-14591. doi: 10.1039/c7nr04734g.

PMID:
28932838
6.

Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers.

Corbo C, Molinaro R, Taraballi F, Toledano Furman NE, Hartman KA, Sherman MB, De Rosa E, Kirui DK, Salvatore F, Tasciotti E.

ACS Nano. 2017 Mar 28;11(3):3262-3273. doi: 10.1021/acsnano.7b00376. Epub 2017 Mar 10.

PMID:
28264157
7.

Vascular Inflammation: A Novel Access Route for Nanomedicine.

Molinaro R, Boada C, Del Rosal GM, Hartman KA, Corbo C, Andrews ED, Toledano-Furman NE, Cooke JP, Tasciotti E.

Methodist Debakey Cardiovasc J. 2016 Sep;12(3):169-174. Review.

8.

A roadmap for academic health centers to establish good laboratory practice-compliant infrastructure.

Adamo JE, Bauer G, Berro M, Burnett BK, Hartman KA, Masiello LM, Moorman-White D, Rubinstein EP, Schuff KG.

Acad Med. 2012 Mar;87(3):279-84. doi: 10.1097/ACM.0b013e318244838a.

9.

Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.

Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS.

Heart. 2012 Mar;98(5):389-94. doi: 10.1136/heartjnl-2011-300823. Epub 2011 Dec 22.

10.

Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.

Berro M, Burnett BK, Fromell GJ, Hartman KA, Rubinstein EP, Schuff KG, Speicher LA; IND/IDE Taskforce of the Clinical and Translational Science Award Consortium.

Acad Med. 2011 Feb;86(2):217-23. doi: 10.1097/ACM.0b013e3182045059.

PMID:
21169787
11.

Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.

Baudhuin LM, Miller WL, Train L, Bryant S, Hartman KA, Phelps M, Larock M, Jaffe AS.

Am J Cardiol. 2010 Aug 1;106(3):402-8. doi: 10.1016/j.amjcard.2010.03.041.

PMID:
20643254
12.

Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm.

Miller WL, Hartman KA, Hodge DO, Hartman S, Struck J, Morgenthaler NG, Bergmann A, Jaffe AS.

J Cardiovasc Transl Res. 2009 Dec;2(4):526-35. doi: 10.1007/s12265-009-9121-x. Epub 2009 Aug 14.

PMID:
20560012
13.

Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure.

Moser DK, Yamokoski L, Sun JL, Conway GA, Hartman KA, Graziano JA, Binanay C, Stevenson LW; Escape Investigators.

J Card Fail. 2009 Nov;15(9):763-9. doi: 10.1016/j.cardfail.2009.05.003. Epub 2009 Jun 25.

14.

Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure.

Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS.

J Am Coll Cardiol. 2009 Oct 27;54(18):1715-21. doi: 10.1016/j.jacc.2009.07.025.

15.

Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide.

Miller WL, Burnett JC Jr, Hartman KA, Hodge DO, Giuliani I, Minard F, Larue C, Jaffe AS.

Clin Chim Acta. 2009 Aug;406(1-2):119-23. doi: 10.1016/j.cca.2009.06.009. Epub 2009 Jun 11.

PMID:
19523938
16.

Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure.

Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS.

Clin Chem. 2009 Jan;55(1):78-84. doi: 10.1373/clinchem.2008.108928. Epub 2008 Nov 21.

17.

Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.

Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, Jaffe AS.

Circulation. 2007 Jul 17;116(3):249-57. Epub 2007 Jun 25.

PMID:
17592074
18.

Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies.

Miller WL, Hartman KA, Burritt MF, Burnett JC Jr, Jaffe AS.

Clin Cardiol. 2007 May;30(5):245-50.

19.

Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial.

Yamokoski LM, Hasselblad V, Moser DK, Binanay C, Conway GA, Glotzer JM, Hartman KA, Stevenson LW, Leier CV.

J Card Fail. 2007 Feb;13(1):8-13.

PMID:
17338997
20.
21.

Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure.

Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr, Jaffe AS.

Clin Chem. 2005 Mar;51(3):569-77. Epub 2004 Dec 22. Erratum in: Clin Chem. 2005 Apr;51(4):798.

22.

A gene coding for a novel protein specific to the olfactory rosettes of Atlantic salmon.

Pang J, Lloyd JM, Rhoads DE, Hartman KA.

J Biomol Struct Dyn. 2002 Feb;19(4):607-17.

PMID:
11843622
23.

Structures of poly(dG-dC) and poly(dA-dT) stabilized by anions.

Loprete DM, Hartman KA.

J Biomol Struct Dyn. 1995 Aug;13(1):57-67.

PMID:
8527031
25.

The existence of unique B structures in polynucleotides with alternating purine-pyrimidine sequences.

Loprete DM, Hartman KA.

Biochem Biophys Res Commun. 1991 Feb 14;174(3):1313-7.

PMID:
1996995
26.

Development and change of young adults' preventive health beliefs and behavior: influence from parents and peers.

Lau RR, Quadrel MJ, Hartman KA.

J Health Soc Behav. 1990 Sep;31(3):240-59.

PMID:
2133479
27.

Existence of the C structure in poly(dA-dC).poly(dG-dT).

Loprete DM, Hartman KA.

J Biomol Struct Dyn. 1989 Oct;7(2):347-62.

PMID:
2557863
28.

Further explorations of common-sense representations of common illnesses.

Lau RR, Bernard TM, Hartman KA.

Health Psychol. 1989;8(2):195-219.

PMID:
2737174
29.

Structural forms and transitions of poly(dG-dC) with Cd(II), Ag(I) and NaNO3.

Keller PB, Loprete DM, Hartman KA.

J Biomol Struct Dyn. 1988 Jun;5(6):1221-9.

PMID:
3271509
30.

Structural forms and transitions for the complex of mercury(II) with poly(dG-dC).

Keller PB, Hartman KA.

J Biomol Struct Dyn. 1987 Jun;4(6):1013-26.

PMID:
3270532
32.

Health as a value: methodological and theoretical considerations.

Lau RR, Hartman KA, Ware JE Jr.

Health Psychol. 1986;5(1):25-43.

PMID:
3720718
33.

The infrared spectrum and structure of the type I complex of silver and DNA.

DiRico DE Jr, Keller PB, Hartman KA.

Nucleic Acids Res. 1985 Jan 11;13(1):251-60.

34.

Structural studies of tobacco mosaic virus and its components by laser Raman spectroscopy.

Fish SR, Hartman KA, Stubbs GJ, Thomas GJ Jr.

Biochemistry. 1981 Dec 22;20(26):7449-57.

PMID:
7326237
35.
36.

Studies of virus structure by laser-Raman spectroscopy. Turnip yellow mosaic virus and capsids.

Hartman KA, McDonald-Ordzie PE, Kaper JM, Prescott B, Thomas GJ Jr.

Biochemistry. 1978 May 30;17(11):2118-23.

PMID:
352393
37.

Studies of virus structure by laser-Raman spectroscopy. II. MS2 phage, MS2 capsids and MS2 RNA in aqueous solutions.

Thomas GJ Jr, Prescott B, McDonald-Ordzie PE, Hartman KA.

J Mol Biol. 1976 Mar 25;102(1):103-24. No abstract available.

PMID:
1271459
38.

The in vitro synthesis of lysozyme, total proteins, and polyphenylalanine by ribosomes containing hydrolyzed ribonucleic acid.

Nolan JC, Hartman KA.

Arch Biochem Biophys. 1975 Jan;166(1):251-7. No abstract available.

PMID:
1092267
39.

The mode of action of divalent cations on the RNase catalyzed hydrolysis of RNA and uridylyl (3'-5') uridine.

Hartman KA, Clayton NW.

Biochem Biophys Res Commun. 1973 Oct 1;54(3):1210-5. No abstract available.

PMID:
4753191
40.

RNase catalyzed hydrolysis of ribosomes in several functional states.

Nolan JC, Hartman KA.

Biochem Biophys Res Commun. 1973 Oct 1;54(3):1216-23. No abstract available.

PMID:
4584882
41.

Raman studies of nucleic acids. X. Conformational structures of Escherichia coli transfer RNAs in aqueous solution.

Thomas GJ Jr, Chen MC, Hartman KA.

Biochim Biophys Acta. 1973 Sep 28;324(1):37-49. No abstract available.

PMID:
4584698
42.

Raman studies of nucleic acids. 8. Estimation of RNA secondary structure from Raman scattering by phosphate-group vibrations.

Thomas GJ Jr, Hartman KA.

Biochim Biophys Acta. 1973 Jun 23;312(2):311-32. No abstract available.

PMID:
4579230
43.

Studies of viral structure by Raman spectroscopy. I. R17 virus and R17 RNA.

Hartman KA, Clayton N, Thomas GJ Jr.

Biochem Biophys Res Commun. 1973 Feb 5;50(3):942-9. No abstract available.

PMID:
4569889
44.

Raman studies of nucleic acids. VI. Conformational structures of tRNA fMet , tRNA Val and tRNA Phe 2 .

Thomas GJ Jr, Medeiros GC, Hartman KA.

Biochim Biophys Acta. 1972 Aug 16;277(1):71-9. No abstract available.

PMID:
4559804
45.

THe dependence of the rate of RNase A catalyzed hydrolysis of ribosomes and rRNA on the concentration of magnesium and ammonium ions.

Hartman KA, Nolan JC, Amaya J.

Biochem Biophys Res Commun. 1971 Dec 3;45(5):1307-11. No abstract available.

PMID:
4944356
46.

The dependence of raman scattering on the conformation of ribosomal RNA.

Thomas GJ, Medeiros GC, Hartman KA.

Biochem Biophys Res Commun. 1971 Aug 6;44(3):587-92. No abstract available.

PMID:
4941645
47.

Secondary structure of ribosomal RNA.

Hartman KA, Thomas GJ Jr.

Science. 1970 Nov 13;170(3959):740-1.

PMID:
4920950
48.

Structure of RNA in ribosomes.

Hartman KA, Amaya J, Schachter EM.

Science. 1970 Oct 9;170(3954):171-3.

PMID:
4917385
49.
50.

Properties of ribosomes and ribosomal RNA formed by a relaxed mutant of Escherichia coli during growth with ethionine.

Cheng TY, Hartman KA Jr.

J Mol Biol. 1968 Jan 28;31(2):191-207. No abstract available.

PMID:
4865482

Supplemental Content

Loading ...
Support Center